Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants
Phase 3
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: Fluarix Tetra Pre-filled SyringeBiological: IL-YANG FLU Vaccine Prefilled Syringe INJ.
- Registration Number
- NCT04381689
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years)
- Detailed Description
The study is an Randomized, Double-blind, Active controlled Phase III study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 245
Inclusion Criteria
- Healthy men or women aged from 6 months to < 3 years
- Subjects were born after full term pregnancy (37 weeks)
- Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 10 years of age (and for subjects younger than 7 years of age for the some institutions)).
Exclusion Criteria
- Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components of the study vaccine
- Subject who had received an influenza vaccine within the last 6 months
- Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
- Subject with a history of Guillain-Barre syndrome
- Subject with Down's syndrome or cytogenetic disorders.
- Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
- Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
- Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
- Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine
- Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
- Subject who had participated in another experimental study within 30 days prior to administration of the study vaccine
- Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GSK PFS Fluarix Tetra Pre-filled Syringe Fluarix Tetra Pre-filled Syringe IL-YANG PFS IL-YANG FLU Vaccine Prefilled Syringe INJ. IL-YANG FLU Vaccine Prefilled Syringe INJ.
- Primary Outcome Measures
Name Time Method Seroconversion rate against Hemagglutination Inhibition(HI) antibody Up to Day28(+7) after the last vaccination Seroconversion rate(a lower bound of 95 CI) ≥ 40%
Seroprotection rate against Hemagglutination Up to Day28(+7) after the last vaccination Seroprotection rate(a lower bound of 95 CI) ≥ 70%
- Secondary Outcome Measures
Name Time Method Geometric Mean Titer(GMT) Up to Day28(+7) after the last vaccination GMT of HI Antibody Titer Before Vaccination and After Vaccination
Geometric Mean Ratio(GMR) Up to Day28(+7) after the last vaccination GMR of HI Antibody Titer Before Vaccination and After Vaccination
Trial Locations
- Locations (2)
Korea University ANSAN Hospital
🇰🇷Ansan-si, Gyeonnggi-do, Korea, Republic of
The Catholic University of Korea, Bucheon St. Mary's Hospital
🇰🇷Bucheon-si, Gyeonnggi-do, Korea, Republic of